151 related articles for article (PubMed ID: 37841441)
1. Study protocol of a phase II clinical trial evaluating the efficacy of neoadjuvant intraperitoneal and systemic albumin-bound paclitaxel combined with camrelizumab and S-1 in the treatment of patients with exfoliative cell-positive gastric cancer.
Lv J; Wu J; Wu H; Ding P; Guo H; Yang P; Tian Y; Liu Y; Zhao Q
Front Oncol; 2023; 13():1201928. PubMed ID: 37841441
[TBL] [Abstract][Full Text] [Related]
2. Predictive Effect of Systemic Immune-Inflammation Index Combined With Prognostic Nutrition Index Score on Efficacy and Prognosis of Neoadjuvant Intraperitoneal and Systemic Paclitaxel Combined With Apatinib Conversion Therapy in Gastric Cancer Patients With Positive Peritoneal Lavage Cytology: A Prospective Study.
Ding P; Yang P; Sun C; Tian Y; Guo H; Liu Y; Li Y; Zhao Q
Front Oncol; 2021; 11():791912. PubMed ID: 35127498
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant intraperitoneal and systemic paclitaxel combined with apatinib and S-1 chemotherapy for conversion therapy in gastric cancer patients with positive exfoliative cytology: a prospective study.
Ding P; Yang P; Tian Y; Guo H; Liu Y; Zhang Z; Zheng T; Tan B; Zhang Z; Wang D; Li Y; Zhao Q
J Gastrointest Oncol; 2021 Aug; 12(4):1416-1427. PubMed ID: 34532099
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Conversion Therapy by Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis: A Prospective Phase II Study.
Yang ZY; Yuan F; Lu S; Xu W; Wu JW; Xi WQ; Shi M; Wang ZQ; Ni ZT; He CY; Yao XX; Zheng YN; Zhu ZL; Liu WT; Zhang J; Zhang H; Li C; Yan C; Yan M; Zhu ZG
Front Oncol; 2022; 12():905922. PubMed ID: 35795055
[TBL] [Abstract][Full Text] [Related]
5. Study of SOX combined with intraperitoneal high-dose paclitaxel in gastric cancer with synchronous peritoneal metastasis: A phase II single-arm clinical trial.
Tu L; Zhang W; Ni L; Xu Z; Yang K; Gou H; Zhu Q; Liu M; Yang Y; Hu J; Qiu M
Cancer Med; 2023 Feb; 12(4):4161-4169. PubMed ID: 36161282
[TBL] [Abstract][Full Text] [Related]
6. [Application of laparoscopic exploration combined with abdominal exfoliative cytology in the diagnosis and treatment of locally advanced gastric cancer].
Ding PA; Liu Y; Guo HH; Yang PG; Tian Y; Fan LQ; Tan BB; Li Y; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Feb; 23(2):170-176. PubMed ID: 32074798
[No Abstract] [Full Text] [Related]
7. Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon II trial.
Beeharry MK; Ni ZT; Yang ZY; Zheng YN; Feng RH; Liu WT; Yan C; Yao XX; Li C; Yan M; Zhu ZG
BMC Cancer; 2020 Mar; 20(1):224. PubMed ID: 32183736
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001).
Shang X; Zhao G; Liang F; Zhang C; Zhang W; Liu L; Li R; Duan X; Ma Z; Yue J; Chen C; Meng B; Ren X; Jiang H
Ann Transl Med; 2022 Feb; 10(4):229. PubMed ID: 35280363
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Camrelizumab in Combination with Docetaxel + S-1 Sequenced by Camrelizumab + S-1 for Stage III (PD-1+/MSI-H/EBV+/dMMR) Gastric Cancer: Study Protocol for a Single-Center, Prospective, Open-Label, Single-Arm Trial.
Dong Z; Ni B; Yang L; Guan Y; Zhu C; Zhao E; Zhao G; Xia X; Zhang Z
Front Surg; 2022; 9():917352. PubMed ID: 35836597
[TBL] [Abstract][Full Text] [Related]
10. Benefits of Surgery After Neoadjuvant Intraperitoneal and Systemic Chemotherapy for Gastric Cancer Patients With Peritoneal Metastasis: A Meta-Analysis.
Gong Y; Wang P; Zhu Z; Zhang J; Huang J; Wang T; Chen J; Xu H
J Surg Res; 2020 Jan; 245():234-243. PubMed ID: 31421368
[TBL] [Abstract][Full Text] [Related]
11. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study.
Yu P; Ye Z; Dai G; Zhang Y; Huang L; Du Y; Cheng X
BMC Cancer; 2020 Nov; 20(1):1108. PubMed ID: 33198674
[TBL] [Abstract][Full Text] [Related]
13. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings.
Ishigami H; Yamaguchi H; Yamashita H; Asakage M; Kitayama J
Gastric Cancer; 2017 Mar; 20(Suppl 1):128-134. PubMed ID: 28028665
[TBL] [Abstract][Full Text] [Related]
14. Impact of skeletal muscle loss during conversion therapy on clinical outcomes in lavage cytology positive patients with gastric cancer.
Ding P; Yang P; Yang L; Sun C; Chen S; Li M; Lowe S; Guo H; Tian Y; Liu Y; Zhao Q
Front Oncol; 2022; 12():949511. PubMed ID: 36313681
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of cytological status of peritoneal lavage fluid during intraperitoneal chemotherapy for gastric cancer with overt peritoneal dissemination.
Emoto S; Kitayama J; Ishigami H; Yamaguchi H; Watanabe T
Ann Surg Oncol; 2015 Mar; 22(3):780-6. PubMed ID: 25216603
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study.
Yang P; Zhou X; Yang X; Wang Y; Sun T; Feng S; Ma X
World J Surg Oncol; 2021 Nov; 19(1):333. PubMed ID: 34809658
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant camrelizumab, nab-paclitaxel, and carboplatin in patients with stage IB-IIIA non-small cell lung cancer (NANE-LC): a study protocol of prospective, single-arm, multicenter, phase II study.
Zhou H; Lin L; Qin T; Ren W; Tan Y; Yang Q; Xu H; Xie X; Chen Y; Liu S; Li X; Li Z; Hu H; Yu Y; Yao H
J Thorac Dis; 2021 Nov; 13(11):6468-6475. PubMed ID: 34992825
[TBL] [Abstract][Full Text] [Related]
18. Reduced preoperative serum albumin and absence of peritoneal dissemination may be predictive factors for long-term survival with advanced gastric cancer with positive cytology test.
Yamashita K; Ushiku H; Katada N; Hosoda K; Moriya H; Mieno H; Kikuchi S; Hoshi K; Watanabe M
Eur J Surg Oncol; 2015 Oct; 41(10):1324-32. PubMed ID: 26251341
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study.
Endo S; Terazawa T; Goto M; Tanaka R; Kato T; Fujitani K; Kawakami H; Sakai D; Kurokawa Y; Tsujinaka T; Shimokawa T; Satoh T
BMC Cancer; 2022 Jul; 22(1):811. PubMed ID: 35870893
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y
BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
